An Open-Label Study For Continued Treatment Access For Participants From The B9991032 Avelumab Study
Enrolling By Invitation
18 years - 99 years
All
Phase
2
15 participants needed
1 Location
Brief description of study
The purpose of the continuation sub-study is to provide continued treatment access for
participants from the B9991032 Parent Study who are deriving benefit from study treatment
as judged by the investigator.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: mutant tumors
-
Age: 18 years - 99 years
-
Gender: All
Male or Female Age 18 or older Volunteer in The B9991032 Parent Study
Updated on
04 Aug 2024.
Study ID: 850837
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
